144 related articles for article (PubMed ID: 9224298)
21. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
23. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
24. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
[TBL] [Abstract][Full Text] [Related]
25. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
[TBL] [Abstract][Full Text] [Related]
26. CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder.
Satyam A; Singh P; Sharma M; Seth A; Sharma A
Biomarkers; 2011 Aug; 16(5):413-21. PubMed ID: 21777169
[TBL] [Abstract][Full Text] [Related]
27. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
28. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer.
Senga Y; Kimura G; Hattori T; Yoshida K
Urology; 1996 Nov; 48(5):703-10. PubMed ID: 8911513
[TBL] [Abstract][Full Text] [Related]
30. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma.
Kageyama S; Isono T; Matsuda S; Ushio Y; Satomura S; Terai A; Arai Y; Kawakita M; Okada Y; Yoshiki T
Int J Urol; 2009 May; 16(5):481-6. PubMed ID: 19389084
[TBL] [Abstract][Full Text] [Related]
31. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
[TBL] [Abstract][Full Text] [Related]
32. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
33. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
[TBL] [Abstract][Full Text] [Related]
34. [The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22].
Chen HQ; Han CZ; Du LL; Cui Y; Pang DZ; Jing JX; Zhao XW; Tian BG; Mi ZG
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun; 41 Suppl():84-6. PubMed ID: 17767866
[TBL] [Abstract][Full Text] [Related]
35. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of bladder cancer by analysis of urinary fibronectin.
Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
[TBL] [Abstract][Full Text] [Related]
37. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer.
Sánchez-Carbayo M; Espasa A; Chinchilla V; Herrero E; Megías J; Mira A; Soria F
Clin Chem; 1999 Nov; 45(11):1944-53. PubMed ID: 10545064
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
[TBL] [Abstract][Full Text] [Related]
39. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
40. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]